Abstract-Inhalation of oxidant gases has been implicated in adverse outcomes in pregnancy, but animal models to address mechanisms and studies to identify potential pregnancy-specific therapies are lacking. Herein, we show that inhalation of bromine at 600 parts per million for 30 minutes by pregnant mice on the 15th day of embryonic development results in significantly lower survival after 96 hours than an identical level of exposure in nonpregnant mice. On the 19th embryonic day, bromine-exposed pregnant mice have increased systemic blood pressure, abnormal placental development, severe fetal growth restriction, systemic inflammation, increased levels of circulating antiangiogenic short fms-like tyrosine kinase-1, and evidence of pulmonary and cardiac injury. Treatment with tadalafil, an inhibitor of type 5 phosphodiesterase, by oral gavage 1 hour post-exposure and then once daily thereafter, attenuated systemic blood pressures, decreased inflammation, ameliorated pulmonary and cardiac injury, and improved maternal survival (from 36% to 80%) and fetal growth. These pathological changes resemble those seen in preeclampsia. Nonpregnant mice did not exhibit any of these pathological changes and were not affected by tadalafil. These findings suggest that pregnant women exposed to bromine may require particular attention and monitoring for signs of preeclampsia-like symptoms. (Hypertension. 2017;70:390-400.
R ecent epidemiological evidence indicates that inhalation of noxious gases, such as NO 2 , N 2 O 3 , SO 2 , and O 3 , during pregnancy is associated with fetal growth restriction (FGR) and the development of preeclampsia-type symptoms. 1, 2 Additional observational studies have further corroborated this association between inhaled toxicants and preeclampsia-like symptoms. For instance, maternal cigarette smoking impairs fetal growth via excess placenta-derived secreted FRP1 (frizzled-related protein 1). 3 In addition, in a state-wide birth cohort, maternal exposure during pregnancy to fine particulate matter (PM2.5) and ozone was positively associated with small for gestational age and low birth weight births. 4 Finally, formaldehyde inhalation has been strongly linked to FGR and adverse outcomes in pregnancy. 5 Exposure to halogens (eg, chlorine [Cl 2 ] or bromine [Br 2 ]) causes significant risk to human populations resulting in both pulmonary and systemic injury followed by death from respiratory and cardiac failure. 6 Over 56 million tons of halogens are produced each year worldwide for use in the manufacture of flame retardants, medicinal compounds, gasoline additives, dyes, and water disinfectants. Accidental exposures during transit of halogens has occurred in Geneva, Switzerland (1988, Br 2 ), Graniteville, SC (2005, Cl 2 ), and Chelyabinsk, Russia (2011, Br 2 ), resulting in significant short-and longterm morbidity and mortality. 7 In addition to major industrial accidents and intentional release of halogens, a common source of halogen inhalation toxicity is swimming pool sanitation accidents. 8 Furthermore, preexisting viral infections increase the severity of lung injury secondary to halogen exposure. 9 Accordingly, there is an extensive body of literature available on halogen inhalation lung injury both in humans and in animal models. 10 Yet, there is a paucity of systematic studies addressing mechanisms of lung and systemic injury caused by halogen gas injury in pregnancy. We observed that exposure of pregnant mice to concentrations of Br 2 , likely to be encountered in the vicinity of industrial accidents, resulted in increased mortality when compared with nonpregnant mice; furthermore, surviving pregnant mice developed preeclampsia-like symptoms, and their fetuses failed to thrive.
Preeclampsia is a life-threatening complication of pregnancy characterized by maternal hypertension and is considered severe when accompanied by pulmonary or systemic pathologies. 11 Preeclampsia is commonly associated with FGR. Circulating factors, in part released by an injured placenta, such as sFLT-1 (soluble fms-like tyrosine kinase-1), sENG (soluble endoglin), and inflammatory cytokines, have been mechanistically linked to features of preeclampsia, such as increased blood pressure, decreased trophoblast maturation and proliferation, and retarded fetal growth. 12, 13 sFLT-1 and sENG, in particular, are thought to promote endothelial dysfunction, by inhibiting VEGF (vascular endothelial growth factor).
14 Because inhibitors of type 5 phosphodiesterase (PDE5 i ) are efficient in treating endothelial dysfunction, they have been used successfully in animal models of preeclampsia and are in clinical trials for the treatment of preeclampsia. 15, 16 We hypothesized that pregnancy sensitizes mice to Br 2 inhalation injury through a potential amplifying effect on endothelial dysfunction by placenta-derived inflammatory and antiangiogenic mediators. We further hypothesized that treatment with the PDE5 i , tadalafil, can counteract pregnancyspecific Br 2 toxicity via a beneficial effect on blood pressure and perfusion. In a series of experiments, we found that exposure of pregnant mice at gestational day 14.5 (E14.5) to Br 2 in concentrations likely to be encountered in industrial accidents 17 (600 ppm for 30 minutes) caused a significantly higher rate of mortality compared with nonpregnant female and male mice. We show that this is associated with severe FGR, cardiac and pulmonary injuries, and development of preeclampsia-like features. Furthermore, maternal mortality and morbidity, as well as FGR, were alleviated by maternal postexposure administration of tadalafil.
Methods
Detailed description of methods, procedures, and reagents used is given in the online-only Data Supplement.
Animals
Pathogen-free, age-matched male (20-25 g ), nonpregnant female (20-25 g), and pregnant female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA) and housed in the University of Alabama at Birmingham Animal Facility under standard conditions with food and water access ad libitum. All procedures were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee (No. 20343).
Exposure of Mice to Br 2
Mice were exposed to Br 2 for 30 or 45 minutes at 600 ppm Br 2 as described previously 10 at E14.5. After exposure, mice were returned to room air. Control mice were exposed to air for 30 or 45 minutes under identical conditions.
Tadalafil Administration
Stock solutions of tadalafil (Santa Cruz Biotechnology, Santa Cruz, CA, SC-208412) were administered to pregnant and nonpregnant mice via oral gavage at 2 mg/kg body weight at 1 hour post-exposure and every 24 hours thereafter. Control mice received equal volumes of sterile saline by gavage.
Statistics
Survival between treatment groups under different experimental conditions and at different time points was evaluated using the Pearson χ 2 test, and Fisher exact test. The overall survival rates were estimated according to the Kaplan-Meier method and compared using the logrank test. To eliminate unequal variances, data were log transformed. No outliers were identified via ROUT (Robust Outlier Regression and Removal). One-way (for pregnant-only variables such as placental analyses) or 2-way (for analyses that included pregnant and nonpregnant data) ANOVA (for ≥3 groups) was used to compare continuous variables. Analysis was conducted using Graphpad Prism version 7 software (La Jolla, CA). A P value <0.05 was considered statistically significant in the 2-tailed statistical tests that were used. All data were represented as mean±SEM.
Results

Br 2 Exposure Causes Higher Mortality and Loss of Body Weight in Pregnant Mice Compared With Nonpregnant Mice
We exposed male and nonpregnant female mice and pregnant mice to Br 2 ( Figure 1A ) at E14.5 to an exposure level that causes minimal lethality in nonpregnant mice (600 ppm for 30 minutes). All mice exposed to Br 2 lost weight similarly by E16.5 ( Figure 1B ). However, nonpregnant mice began to gain weight after E16.5. In contrast, pregnant mice continued to lose weight until either death or euthanasia at E18.5.
Male and nonpregnant female mice exposed to Br 2 at 600 ppm for 30 minutes had a mean survival of 80% within 5 days post-exposure. However, pregnant females exposed to Br 2 had significantly lower mean survival (36%) than nonpregnant mice. Treatment of Br 2 -exposed mice with tadalafil postexposure increased survival to 80%. In addition, tadalafil had no effect on mortality in nonpregnant mice exposed to similar or even greater doses of Br 2 ( Figure  S1 in the online-only Data Supplement). These data suggest a pregnancy-specific mechanism of injury. Subsequent studies were performed to identify potential mechanisms involved.
Br 2 Inhalation Injury Causes Severe FGR, and Treatment With Tadalafil Partially Rescues Fetal Growth
Pregnant mice were exposed to Br 2 at 600 ppm for 30 minutes or air at E14.5 and then returned to room air with or without tadalafil at 2 mg/kg by gavage daily, starting 1 hour post-Br 2 exposure. Fetal length, measured at E14.5, E16.5, and E18.5 in utero with echosonography ( Figure 1C) , was decreased at both E16.5 and E18.5 when compared with air controls ( Figure 1D ). Tadalafil treatment returned fetal lengths to air control levels by E18.5 ( Figure 1D and 1E) . Also, fetuses of pregnant mice exposed to 600 ppm Br 2 for 30 minutes weighed less when compared with fetuses of air-breathing mice ( Figure 1E) ; administration of tadalafil increased fetal weight. Fetuses of Br 2 -exposed mice showed no signs of viability (breathing, movement, or skin turning pink) after delivery via cesarean section on E18.5, as opposed to the fetuses of air-exposed mice which all demonstrated these signs. Even though fetuses of mice exposed to Br 2 exhibited no signs of viability when delivered at E18.5 by cesarean section, previous ultrasonography at E18.5 detected heartbeats in all but 1 fetus. With such a marked decrease in fetal growth after Br 2 exposure, we next investigated whether this was because of injury to the placenta.
Br 2 Inhalation Injury Hinders Placenta Development and Induces Inflammation and Production of the Antiangiogenic Molecule sFLT-1
Fetal growth is dependent on normally developing placenta, and abnormal placenta development or placenta injury can negatively affect maternal physiology by sustaining an inflammatory state and producing antiangiogenic molecules. As shown in Figure 2A through 2C, there were significant reductions of the placental junctional zones in mice exposed to Br 2 (despite similar placental weights) and a return to baseline values in tadalafil-treated mice. Visualization of glycogen-containing cells by PAS staining and detection of CDX2 by immunohistochemistry corroborated the findings of altered placenta development by detecting a reduced area occupied by glycogen-containing and CDX2-positive cells. Pregnant (P) mice exhibit increased body weight loss and mortality and fetal growth restriction. Nonpregnant (NP) and P gestational day 14.5 (E14.5) mice were exposed to air or to Br 2 at 600 ppm for 30 min and returned to room air; they received tadalafil (TAD; 2 mg/kg body weight in 0.1 mL of sterile saline) or vehicle via oral gavage at 1 h post-exposure and every 24 h thereafter. Body weights and survival times were recorded daily. A, Kaplan-Meyer curves of P and NP mice with TAD or vehicle, post-Br 2 exposure. NP mice exposed to Br 2 and returned to room air lived longer than similarly exposed P mice (*P<0.05). TAD improved survival times of P mice post-Br 2 (#P<0.05) but not of NP mice; n=10-19; Log-rank test. B, Body weights normalized to weights of air-exposed mice. P mice exposed to Br 2 and returned to room air exhibit more severe weight loss compared with similarly exposed NP mice (*P<0.05). TAD administration mitigated weight loss in P mice at 4 d post-exposure but has no effect in NP mice; n=6-8; ANOVA. C, Representative ultrasound of a fetus showing how fetal length was measured. D, Summary data of fetal length measurements at E14.5, E16.5, and E18.5. Exposure to Br 2 resulted in decreased fetal lengths which were restored to their air control values at E18.5 in the TAD group; n=6-10 pups (2 pups per litter) for each condition; ANOVA; P values when compared with the corresponding air controls for the indicated gestational age. E, Representative photograph of paraformaldehyde-fixed fetuses at E18.5 for the indicated conditions. Fetuses of Br 2 -exposed P mice exhibit severe fetal growth restriction, and TAD improves fetal growth. F, Fetal weights were recorded after extraction of fetuses at E18.5. Fetal weights of fetuses from Br 2 -exposed P mice weighed considerably less and were partially rescued by TAD; n=pups (11-25; 2 pups per litter); ANOVA. All data are means±SEM.
Placental TNF-α (tumor necrosis factor-α) mRNA was significantly reduced in Br 2 -exposed mice that received tadalafil ( Figure 2D ). This indicated a less inflamed state in placentas of Br 2 -exposed mice with PDE5 inhibition. sFLT-1:FLT-1 mRNA ratio increased in placentas of mothers exposed to Br 2 ( Figure 2E ). Tadalafil therapy post-Br 2 decreased the sFLT-1:FLT-1 mRNA ratio to air control levels. These changes in sFLT-1 mRNA levels were reflected by a 5-fold increase of circulating sFLT-1 levels in maternal plasma of Br 2 -exposed mice, which was normalized by tadalafil therapy ( Figure 2F ).
Pregnant Mice Exhibit Signs of Severe Lung Injury 96 Hours Post-Br 2 Exposure, Which Are Absent in Nonpregnant Mice
Br 2 inhalation in nonpregnant animals is known to cause a temporary increase in alveolar epithelial permeability. This leads to increased protein content in the bronchoalveolar lavage (BAL) fluid, which begins to resolve after 3 days. 10 Our data show that nonpregnant mice exposed to 600 ppm for 30 minutes have lung wet/dry weight ratios and BAL fluid protein values similar to those of the corresponding air controls 3 days post-exposure. Pregnant mice, however, had increased Figure 2 . Exposure of pregnant mice to Br 2 damages their placentas. Pregnant gestational day 14.5 (E14.5) mice were exposed to air or 600 ppm Br 2 for 30 min, returned to room air and received tadalafil (TAD) or vehicle. A and B, Representative hematoxylin and eosin stained (A) placenta sections at E18.5 with the junctional zone demarcated with yellow highlighting (A) and (B) periodic acid-Schiff staining (left) and CDX2 staining (right) of Br 2 -exposed pregnant mice revealed a reduced junctional zone (B: black bars) at E18.5; TAD administration restored junctional zones to normal size. C, Junctional zone areas at E18.5 for the indicated groups; n=9-20; ANOVA. D and E, TNF-α (tumor necrosis factor-α) mRNA (n=6-23) was reduced in Br 2 -exposed pregnant mice treated with TAD. sFLT-1 (soluble fms-like tyrosine kinase-1)/FLT-1 mRNA (n=12-18) was increased in placentas of Br 2 -exposed pregnant mice at E18.5 (ANOVA) and was reduced to air control values by TAD. F, sFLT-1 in plasma at E18.5 increased in pregnant mice exposed to Br 2 and was reduced with TAD; ANOVA. Only 1 placenta per pregnant mother was used. All data are means±SEM.
lung wet/dry weight ratios and BAL fluid protein at E18.5. Treatment with tadalafil significantly reduced wet/dry lung weight ratios and BAL fluid protein ( Figure 3A and 3B) . P a O 2 was unaffected by Br 2 inhalation ( Figure 3C) ; however, there was a significant increase of P a CO 2 in pregnant mice ( Figure 3D ) accompanied by a severe drop in pH (to 7.05; Figure 3E ). These findings are consistent with alveolar hypoventilation. Similar findings have been reported in sheep exposed to 100% oxygen at 1 atmosphere absolute for 3 to 4 days. 18 Tadalafil administration had no significant effect on P a CO 2 , but significantly increased arterial pH to 7.18, presumably because of an increase of bicarbonate. Bloodoxygen saturation was significantly decreased in Br 2 -exposed pregnant mice and was restored by tadalafil administration ( Figure 3F ).
Br 2 Inhalation Causes Systemic Hypertension in Pregnant Mice
A life-threatening complication of pregnancy is severe hypertension, the cause of which is driven by placental inflammation and injury and production of antiangiogenic mediators, such as sFLT-1. Both systemic systolic and Figure 3 . Pregnant mice exhibit pulmonary injury 96 h post-exposure. Nonpregnant and pregnant gestational day 14.5 (E14.5) mice were exposed to air or 600 ppm Br 2 for 30 min, returned to room air, then administered tadalafil (TAD) or vehicle. A, Lung wet/dry weight ratios at E18.5 are increased in pregnant mice exposed to Br 2 and are reduced by TAD. B, Protein concentrations in the bronchoalveolar lavage fluid (BALF) of pregnant mice were increased at E18.5 and returned to the air control values after administration of TAD. diastolic blood pressures of nonpregnant mice exposed to Br 2 were unchanged when compared with nonpregnant air controls. Systolic pressures in pregnant mice exposed to Br 2 were not significantly increased ( Figure 4A ). However, there was a 40% increase of systemic diastolic blood pressures in pregnant mice at E18.5. In addition, these values returned to baseline in tadalafil-treated mice ( Figure 4B ). Right ventricle pressures were unchanged in Br 2 -exposed pregnant mice ( Figure 4C ; Figure S2 ).
Br 2 Inhalation Causes Decreased Cyclic Guanosine Monophosphate Levels in Pregnant Mice
We hypothesized that changes in lung and aortic cyclic guanosine monophosphate (cGMP) levels may account for the Figure 4 . Exposure to Br 2 increases the systemic blood pressure of pregnant mice and decreases cGMP in the lungs, placentas, and aortas. Nonpregnant and pregnant gestational day 14.5 (E14.5) mice were exposed to air or 600 ppm Br 2 for 30 min, returned to room air, then administered tadalafil (TAD) or vehicle. At E18.5, a pressure transducer catheter was inserted into either the aortic arch via the carotid or into the right ventricle through the jugular vein in anesthetized mice. A and B, Br 2 has no significant effect on systemic systolic or diastolic blood pressures in nonpregnant mice. However, systemic diastolic pressures were increased in pregnant mice. Both systemic systolic and diastolic pressures were decreased to their corresponding air controls after TAD administration; n=6-11; ANOVA. C, Right ventricular (RV) systolic pressures remained unchanged in pregnant mice exposed to Br 2 . D-F, Lung tissue, placenta, and aorta cGMP levels of Br 2 -exposed pregnant mice decreased significantly. Lung and placenta cGMP levels were restored after TAD administration; n=6-7 per group; ANOVA. All data are means±SEM.
systemic hypertension seen in pregnant mice exposed to Br 2 . cGMP levels in pregnant mice were decreased significantly when compared with air controls in the lung, placenta, and aorta ( Figure 4D through 4F) . Treatment with tadalafil increases cGMP values in the lung and placenta.
Br 2 Increases Circulating Inflammatory Cytokines
At E18.5, circulating levels of TNF-α and KC/GRO (keratinocyte chemoattractant/growth-related oncogene, the murine functional equivalent of human IL-8 [interleukin-8]) were increased only in the pregnant, Br 2 -exposed mice. IL-6 was increased in both nonpregnant and pregnant mice exposed to Br 2 . These cytokines have been shown to be associated with the onset of preeclampsia. 12, [19] [20] [21] [22] [23] [24] Tadalafil therapy subsequently reduced these levels to those similar to air controls ( Figure 5A through 5C).
Br 2 Inhalation Decreases Cardiac Function in Pregnant Mice That Is Reversed by Tadalafil
At E18.5, cardiac output calculated from echo Doppler analysis ( Figure 6A ) was diminished in pregnant mice exposed to Br 2 when compared with air-exposed control pregnant mice ( Figure 6B ). Administration of tadalafil restored cardiac output. Ejection fraction ( Figure 6C ), fractional shortening, and heart rate were unaffected in any of the experimental groups, but stroke volume was reduced in Br 2 -exposed pregnant mice. Left ventricle end-diastolic volumes were decreased in Br 2 -exposed pregnant mice ( Figure 6E ), explaining the decrease of left ventricular cardiac output despite the preserved ejection fraction. These findings are consistent with the presence of heart failure with preserved ejection fraction, historically referred to as diastolic heart failure.
Discussion
We show for the first time that exposure of pregnant mice to the oxidant and electrophile gas Br 2 , in concentrations likely to be encountered in the vicinity of industrial accidents, results in significant mortality and morbidity when compared with male and nonpregnant female mice exposed to identical concentrations of Br 2 . Pregnant mice experienced severe injury to their placentas resulting in the release of inflammatory cytokines and the antiangiogenic molecule sFLT-1 in the plasma, FGR, and increased systemic diastolic pressures and noncardiogenic pulmonary edema. These symptoms are reminiscent of those seen in pregnant women with preeclampsia.
One factor that may account for this preeclampsia-like condition is the observed decrease of cGMP in lungs, aorta, and placenta. This may be caused by increased breakdown of cGMP by PDE5 or decreased production caused by the systemic inactivation of endothelial nitric oxide synthase (eNOS) as seen in mice and rats after exposure to Cl 2 .
25 PDE5 i have shown therapeutic benefit in animal models of preeclampsia, 26, 27 and the most widely used PDE5 i , sildenafil, is in human clinical trials to treat preeclampsia. 15, 16 These protective effects are most likely because of the inhibition of cGMP breakdown by PDE5 and prevention of hypertension. We chose to administer the PDE5 i tadalafil because of its long half-life (17.5 hours) and its specificity. For example, tadalafil is >700× more potent for PDE5 than for PDE6 and at least 9000× more potent for PDE5 than PDE1 to PDE4 and PDE7 to PDE10.
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Figure 5. Pregnant mice exposed to Br 2 demonstrated systemic inflammation at gestational day 18.5 (E18.5). Nonpregnant and pregnant (E14.5) mice were exposed to air or 600 ppm Br 2 for 30 min, returned to room air, then administered tadalafil (TAD) or vehicle. A-C, Plasma TNF-α (tumor necrosis factor-α), IL-6 (interleukin-6), and KC/GRO (keratinocyte chemoattractant/growthrelated oncogene) increased in pregnant mice exposed to Br 2 , but only IL-6 increased in nonpregnant mice post-Br 2 . All 3 cytokines in pregnant mice exposed to Br 2 returned to air control values after TAD administration; n=6-12 per group; ANOVA. All data are means±SEM.
However, the protective effects of restoring cGMP may be because of a variety of additional mechanisms. cGMP has also been shown to maintain endothelial barrier function 29 and increase sodium-dependent alveolar fluid clearance via regulation of epithelial Na +30 and K + channels. 31 This may explain the restoration of blood gas permeability and resolution of pulmonary edema seen in pregnant mice that received tadalafil post-Br 2 exposure. In the placenta, which lacks significant smooth muscle, cGMP-dependent mechanisms have been shown to participate in maintaining trophoblast survival and invasiveness. 32 Therefore, it is plausible that some of the beneficial effects of tadalafil therapy were mediated by direct effect on the trophoblasts. Furthermore, within the limits of this study, we were unable to exclude any offtarget effects (eg, inhibition of other PDEs) of tadalafil. . Br 2 -exposed pregnant mice exhibit diminished cardiac function at gestational day 18.5 (E18.5). Nonpregnant and pregnant (E14.5) mice were exposed to air or 600 ppm Br 2 for 30 min, returned to room air, then administered tadalafil (TAD) or vehicle. A, Representative echosonography left ventricular (LV) and right ventricular (RV) traces at E18.5 of pregnant mice exposed to air or Br 2 with demarcation of ventricular sizes. B, Cardiac output (LV) determined by echosonography was decreased in Br 2 -exposed pregnant mice, which increased after administration of TAD; ANOVA: n=6-8. C, Ejection fraction (LV) was unchanged in all groups; ANOVA. D, LV endsystolic volume was similar in all groups. E, However, LV end-diastolic volume was diminished in Br 2 -exposed pregnant mice; n=6-8; ANOVA. All data are means±SEM. A indicates area; A;s, area systole; A;d, area diastole; FAC, fractional area change; and HR, heart rate.
Exposure to Br 2 represents a clear danger to public health. World production of Br 2 exceeds 300 000 tons per year; it is used in the manufacturing of medicinal compounds, flame retardants, agricultural chemicals, gasoline additives, dyes, photographic chemicals, bleaching agents, and water disinfectants. It is produced in central facilities and transported by trains or trucks. A major accident recently occurred during railway Br 2 transport in the city of Chelyabinsk, Russia (population 1.1 million), resulting in 42 people being hospitalized and over 200 individuals seeking medical attention. 33 A study conducted on human volunteers demonstrated that a small exposure to 0.9 ppm Br 2 for 5 minutes results in cough, headache, and irritation of the eyes, nose, and upper respiratory tract. 34 Accidental exposure to higher doses of Br 2 and its ensuing respiratory complications can lead to severe morbidity and mortality, yet there is a lack of human and animal data available on Br 2 toxicity, especially during pregnancy. This is particularly pertinent because, according to the US census bureau, 4% of women in the United States are pregnant at any given time. Interestingly, 2 epidemiological studies in western Australia and the southern United States reported associates among levels of halogenated intermediates in drinking water (used as disinfectants) and premature births 35 and birth defects. The exact mechanism by which Br 2 inhalation induces placental injury remains unclear. Br 2 and hypobromous acid are strong oxidants, likely to react with targets on the plasma membranes of lung epithelial cells (such as plasmalogens), forming secondary, longer living intermediates, such as 2-bromopalmitaldehyde and 2-bromostearaldehyde (together referred to as 2-BrFALD) which may be oxidized to 2-bromopalmitic acid and 2-bromostearic acid (together referred to as 2-BrFA) capable of transducing injury to distal sites. 37 2-bromopalmitic acid is a potent inhibitor of mitochondrial fatty acid oxidation and of protein palmitoylation. 38, 39 In addition, in eosinophils, the catalytic action of eosinophil peroxidase on hydrogen peroxide and bromide generates 2-bromo fatty aldehyde. 37 Normal physiological concentrations of bromide are in the range of 20 to 150 µmol/L and will most likely rise in the mmol/L range after inhalation of Br 2 gas. Thus, production of 2-bromo fatty aldehyde by inhaled Br 2 and inflammatory cell myeloperoxidase is likely to occur. Recently Ford et al 40 showed that the formation of 2-chloropalmitaldehyde, 2-chlorostearaldehyde, and their oxidized products, free and esterified 2-chloropalmitic acid and 2-chlorostearic acid, could be detected in the lungs and plasma of mice and rats for ≤72 hours postexposure to 400 ppm Cl 2 for 30 minutes. Furthermore, intranasal administration of 2-chloropalmitic acid or 2-chloropalmitaldehyde resulted in increased distal lung permeability and inflammation and systemic endothelial dysfunction characterized by loss of eNOS-dependent vasodilation. Thus, reactive intermediates formed during halogen inhalation are capable of causing distal organ injury and may be responsible both for placental and cardiac injury. In another study, Zaky et al 41 demonstrated that perfusion of isolated hearts with chloramines (another long-term intermediate formed during Cl 2 inhalation) resulted in severe cardiac dysfunction.
Placental injury can be induced by a variety of agents that induce endothelial dysfunction, including antagonists of eNOS, 42 genetic ablation of endothelial eNOS in gene-targeted mice, 43 exogenous administration of the VEGF antagonist sFLT-1, 44 or the short form of endoglin. 45 In these models, placental injury or decreased uterine/placental perfusion leading to placental ischemia causes placental inflammation and the production of antiangiogenic molecules which, in turn, aggravate systemic endothelial dysfunction and worsen vasoconstriction that further aggravates placenta injury. 46 In Br 2 -exposed pregnant mice, we were able to clearly demonstrate placental injury by evaluating placenta development based on the size of the junctional zone and by detecting inflammation and increased production of sFLT-1 by quantifying their respective mRNA levels. We also detected increased circulating sFLT-1 and decreased vascular and tissue cGMP levels that is considered to be a diagnostic sign of decreased VEGF signaling. Acting as a decoy receptor for VEGF, sFLT-1 inhibits maternal VEGF signal transduction resulting in endothelial dysfunction, vasoconstriction, and hypertension.
Similarly, inflammatory cytokines may play an important role in injuring the placenta. TNF-α and IL-6 have been well established as circulating biomarkers in human preeclampsia and have been shown to be causative in pathogenesis in experimental animal models of preeclampsia. 20, 47, 48 Recently, IL-8 has been shown to be associated with preeclampsia in humans. 49 Indeed, our analysis of plasma cytokines determined that pregnant mice exposed to Br 2 exhibited significant elevation of all 3 of these proinflammatory mediators, whereas there were no significant differences in cytokine or chemokine levels (except IL-6) at this time point in nonpregnant mice. These data indicate the presence of systemic inflammation in pregnant mice post-Br 2 , which may contribute to the observed injuries to cardiac and pulmonary systems.
An additional intriguing factor in our studies is the development of severe respiratory acidosis in the pregnant mice, which is caused by alveolar hypoventilation. Respiratory acidosis contributed to pulmonary hypertension, cardiac dysfunction and placenta hypoperfusion and injury. 50, 51 Interestingly, tadalafil administration did not decrease P a CO 2 ; however, it had a significant therapeutic effect by normalizing the arterial pH.
In human clinical studies, left ventricular diastolic dysfunction has been observed in preeclampsia. 52 In cases when preeclampsia was accompanied with pulmonary edema, diastolic dysfunction was highly prevalent. 53 We observed decreased cardiac output in pregnant mice exposed to Br 2 , and this was accompanied with a decreased filling of the left ventricle under diastole but also accompanied with preserved ejection fraction. In addition to pulmonary edema, we also observed increased BAL fluid protein, indicating that both barriers at the air-blood interface have been compromised.
Conclusions
Our data show conclusively that pregnant C57BL/6 mice exposed to Br 2 at E14.5 exhibit increased mortality when compared with nonpregnant mice and display signs of placental damage accompanying symptoms reminiscent of preeclampsia. Potential mechanisms involved are shown in Figure S3 . Tadalafil, the orally available, long-acting PDE5 i , administered after Br 2 exposure, increases survival exclusively in pregnant mice and eliminates signs of placental damage. The key mechanistic driver of pathology, similar to models of preeclampsia, seems to be a positive feedback loop between endothelial dysfunction and the placenta via the antiangiogenic sFLT-1. The resulting increased vascular resistance is likely combined with additional cGMP-mediated mechanisms in nonvascular tissues such as the damage to alveolar epithelium and trophoblasts in the placenta. Damage to the placenta and eNOS is likely mediated by long-acting mediators formed by the interaction of inhaled Br 2 with plasmalogens, as recently reported in Cl 2 -exposed mice, as well as inflammatory cytokines and chemokines. This is the first demonstration that a brief exposure of pregnant mice to an oxidant and electrophile gas (Br 2 ) results in extensive injury to the placenta, initiating a cycle of events leading to significant morbidity and mortality.
Perspectives
In summary, we have determined that exposure to Br 2 causes preeclampsia-like signs and increased mortality in pregnant mice. These signs include hypertension, placental injury, and FGR that are accompanied by increased pulmonary and cardiac injury. We demonstrate that Br 2 decreased cGMP in multiple tissues, including the vasculature. Administering the PDE5 i tadalafil restores cGMP levels and reduces signs of injury seen in pregnant mice exposed to Br 2 . 
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